MX2020004545A - Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa. - Google Patents
Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa.Info
- Publication number
- MX2020004545A MX2020004545A MX2020004545A MX2020004545A MX2020004545A MX 2020004545 A MX2020004545 A MX 2020004545A MX 2020004545 A MX2020004545 A MX 2020004545A MX 2020004545 A MX2020004545 A MX 2020004545A MX 2020004545 A MX2020004545 A MX 2020004545A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline salt
- adp
- ribose
- tricyclic
- poly
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 title 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 title 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title 1
- 229940123066 Polymerase inhibitor Drugs 0.000 title 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 abstract 2
- 229950004707 rucaparib Drugs 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17199999 | 2017-11-03 | ||
| PCT/EP2018/079815 WO2019086509A1 (fr) | 2017-11-03 | 2018-10-31 | Sel cristallin d'un inhibiteur de poly(adp-ribose) polymérase tricyclique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004545A true MX2020004545A (es) | 2020-08-03 |
Family
ID=60245005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004545A MX2020004545A (es) | 2017-11-03 | 2018-10-31 | Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3704124A1 (fr) |
| JP (1) | JP2021501771A (fr) |
| CA (1) | CA3080657A1 (fr) |
| MX (1) | MX2020004545A (fr) |
| WO (1) | WO2019086509A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021156140A1 (fr) | 2020-02-03 | 2021-08-12 | Sandoz Ag | Polymorphe de mésylate de rucaparib |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6495541B1 (en) | 1999-01-11 | 2002-12-17 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| JP4756229B2 (ja) * | 2000-05-10 | 2011-08-24 | 日本農薬株式会社 | １，３−ジヨードヒダントイン類の製造方法 |
| CA2520997A1 (fr) * | 2003-03-31 | 2004-10-14 | Stacie Sara Canan-Koch | Sels d'inhibiteurs tricycliques de poly(adp-ribose) polymerases |
| ATE551345T1 (de) * | 2004-09-22 | 2012-04-15 | Pfizer | Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on |
| EP4166558A1 (fr) * | 2010-02-12 | 2023-04-19 | Pfizer Inc. | Sels et polymorphes de 8-fluoro-2-{4-[(méthylamino} méthyl] phényl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one |
-
2018
- 2018-10-31 EP EP18795631.3A patent/EP3704124A1/fr not_active Withdrawn
- 2018-10-31 MX MX2020004545A patent/MX2020004545A/es unknown
- 2018-10-31 JP JP2020524591A patent/JP2021501771A/ja active Pending
- 2018-10-31 WO PCT/EP2018/079815 patent/WO2019086509A1/fr not_active Ceased
- 2018-10-31 CA CA3080657A patent/CA3080657A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3080657A1 (fr) | 2019-05-09 |
| JP2021501771A (ja) | 2021-01-21 |
| EP3704124A1 (fr) | 2020-09-09 |
| WO2019086509A1 (fr) | 2019-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20020410A (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
| DOP2019000201A (es) | Compuestos inhibidores del vih | |
| NI201900062A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| MX385876B (es) | Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante. | |
| UY35916A (es) | Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio | |
| SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
| UY36212A (es) | Moduladores de receptores tipo toll para el tratamiento del vih | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| MX377384B (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer. | |
| CL2018002784A1 (es) | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue. | |
| CO2018003471A2 (es) | Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue | |
| CO2018003369A2 (es) | Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue | |
| UY36340A (es) | Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
| BR112017003705A2 (pt) | compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea | |
| MX2016014826A (es) | Conjugados de peptido-curcumina y formulaciones de los mismos. | |
| BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
| MX2020008360A (es) | Forma cristalina de bictegravir sodico. | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| MX2020004545A (es) | Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa. | |
| MX2019009810A (es) | Formas cristalinas de cabotegravir de sodio. | |
| BR112017027082A2 (pt) | composição farmacêutica, método para tratar infecção, extrato, método para reduzir a carga viral | |
| MX2018012587A (es) | (+)-azasetron para uso en el tratamiento de trastornos del oido. | |
| CO2018005367A2 (es) | Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico |